 Analysts expect that Aimmune Therapeutics Inc NASDAQ:AIMT will report 1.75 million in sales for the current quarter, according to Zacks Investment Research. Six analysts have issued estimates for Aimmune Therapeutics earnings, with the highest sales estimate coming in at 7.30 million and the lowest estimate coming in at 510,000.00. The firm is expected to announce ... 